ProfileGDS5678 / 1418991_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 77% 75% 83% 77% 73% 77% 74% 76% 76% 76% 77% 78% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0643476
GSM967853U87-EV human glioblastoma xenograft - Control 25.2980977
GSM967854U87-EV human glioblastoma xenograft - Control 34.9950675
GSM967855U87-EV human glioblastoma xenograft - Control 46.1714883
GSM967856U87-EV human glioblastoma xenograft - Control 55.3034477
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6696473
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1279177
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8006374
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1049876
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.068176
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1399476
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2103677
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4147178
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0327576